You are here

Viatris

FDA grants tentative approval for Viatris’ pediatric HIV drug

FDA grants tentative approval for Viatris’ pediatric HIV drug

Business Today

dolutegravir/lamivudine

Flag link:

In win for generics industry, Viatris wards off $50M payment in tax battle with IRS

In win for generics industry, Viatris wards off $50M payment in tax battle with IRS

Fierce Pharma

Flag link:

Study: Biosimilars ‘fulfilling their promise’ of lowering biologic prices

Study: Biosimilars ‘fulfilling their promise’ of lowering biologic prices

BioSpace

Teva Pharmaceutical

Flag link:

J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza

J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza

Fierce Pharma

Flag link:

Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi

Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi

Fierce Pharma

Flag link:

Viatris maintains legal winning streak with yet another EpiPen antitrust victory

Viatris maintains legal winning streak with yet another EpiPen antitrust victory

Fierce Pharma

Flag link:

Merck, Viatris agree to settle patent feud surrounding diabetes drugs

Merck, Viatris agree to settle patent feud surrounding diabetes drugs

Endpoints

Flag link:

US government, Pfizer and others side with Sanofi and Regeneron in Supreme Court patent case

US government, Pfizer and others side with Sanofi and Regeneron in Supreme Court patent case

Endpoints

Flag link:

FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks

FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks

Endpoints

drug manufacturing

Flag link:

AZ wins patent fight with Viatris, gains more exclusivity for blockbuster Symbicort

AZ wins patent fight with Viatris, gains more exclusivity for blockbuster Symbicort

Fierce Pharma

Flag link:

EpiPen litigation comes back to haunt Teva a decade after initial settlements

EpiPen litigation comes back to haunt Teva a decade after initial settlements

Fierce Pharma

Teva Pharmaceutical

Flag link:

Viatris executive charged in insider trading scheme that allegedly netted $7.2 million

Viatris executive charged in insider trading scheme that allegedly netted $7.2 million

Fierce Pharma

insider trading

Flag link:

Viatris to buy two eye drug developers in deals worth up to $750M

Viatris to buy two eye drug developers in deals worth up to $750M

BioPharma Dive

Oyster Point Pharma

Famy Life Sciences

Flag link:

Viatris weighs sale of European consumer health business — report

Viatris weighs sale of European consumer health business — report

Endpoints

consumer health

Flag link:

Merck celebrates another win in Januvia patent battle against Viatris

Merck celebrates another win in Januvia patent battle against Viatris

Endpoints

Flag link:

Merck pulls a patent win for diabetes franchise in West Virginia federal court

Merck pulls a patent win for diabetes franchise in West Virginia federal court

Endpoints

Flag link:

J&J's Momenta calls infringement against Viatris' Copaxone generic, but why now?

J&J's Momenta calls infringement against Viatris' Copaxone generic, but why now?

Fierce Pharma

Momenta Pharmaceuticals

drug manufacturing

Flag link:

Takeover-driven resurgence fails to materialize for biotech

Takeover-driven resurgence fails to materialize for biotech

EP Vantage

Halozyme Therapeutics

Samsung Bioepis

Flag link:

The mysterious case of Viatris and the missing insulin label deepens

The mysterious case of Viatris and the missing insulin label deepens

Fierce Pharma

product recalls

Flag link:

FDA clears first generic of AZ’s blockbuster Symbicort

FDA clears first generic of AZ’s blockbuster Symbicort

Pharmaforum

Flag link:

Pages